Walmart Agrees To Pay $50M in DOJ Settlement Over Alleged Opioid Prescriptions at Its Pharmacies

Walmart has agreed to pay $50 million (roughly equivalent to €42.5 million or £38 million) to settle a Justice Department lawsuit accusing its pharmacies of unlawfully filling thousands of invalid prescriptions for opioids and other controlled substances, the department announced on Friday.

The agreement resolves a case first brought against the retailer in December 2020 and closes one of the most significant single company actions to emerge from America's opioid crisis.

The original complaint was filed in the US District Court for the District of Delaware and later amended in 2022. It alleged that from 26 June 2013 onwards, Walmart's compliance team and its own pharmacists knowingly filled prescriptions written by doctors operating as so called 'pill mills,' even after staff flagged concerns internally.

According to the Justice Department, pharmacists submitted thousands of 'refusal to fill' forms warning about suspicious prescribing, yet one compliance director reportedly wrote in an internal email that chasing sales and 'patient awareness' was a better use of managers' time than reviewing those warnings.

Compliance Failures at the Heart of the Walmart Case

The government's case rested heavily on red flags that pharmacists allegedly ignored, including dangerous combinations of opioids, so called drug cocktails mixing opioids with other medications, and repeated early refill requests for commonly abused pills.

Associate Attorney General Stanley Woodward said in a statement that the settlement 'proves this Department is committed to putting Americans' flourishing first,' adding that companies dispensing controlled substances would be held to their legal obligations regardless of profit motive.

DEA Assistant Administrator Cheri Oz struck a similarly firm tone. 'This $50 million settlement makes clear that pharmacies have a responsibility to identify and prevent the unlawful dispensing of controlled substances,' she stated, warning that filling illegitimate prescriptions 'puts patients and communities at risk' and undermines safeguards meant to stop drugs being diverted or misused.

She added the deal was designed both to address past conduct and to tighten compliance going forward.

As part of the settlement, Walmart has entered a memorandum of agreement with the DEA requiring it to set up a hotline for employees and patients to report suspected illegal dispensing. The retailer must also proactively monitor dispensing patterns across its pharmacy network and build a formal process for evaluating prescribers suspected of writing improper scripts.

Crucially, the Justice Department stressed that the claims resolved are allegations only, with no determination of liability made against the company.

What the Walmart Settlement Means Going Forward

This isn't Walmart's first brush with opioid litigation, not by a long way. In 2022, the company agreed to pay $3.1 billion to resolve thousands of lawsuits brought by states and local governments over similar allegations concerning its pharmacy operations, a far larger sum reflecting the scale of that separate multi state action.

Other pharmacy chains have faced comparable reckonings. CVS and Walgreens reached similar, larger settlements.

The human cost behind these settlements remains staggering. More than 905,000 people in the US died from opioid overdoses between 1999 and 2025, according to the US Centers for Disease Control and Prevention, with annual deaths beginning to decline after 2022. That figure underscores why federal regulators keep pursuing these cases even when the eventual payouts look modest against the scale of the alleged conduct.

Walmart said in a statement: 'We are pleased to resolve this matter and will continue supporting the exceptional work our pharmacists do every day to provide outstanding patient care.' In a regulatory filing, the company called the settlement amount 'immaterial.'